Vyvgart Ignites the FcRn Drug War
Quarterly Sales Surpass 2 Trillion Won, Indications Continue to Expand
HanAll Biopharma Leads the Clinical Race in Korea
Celltrion Also Developing Long-Acting Therapies

Beginning as a treatment for rare diseases, neonatal Fc receptor (FcRn) inhibitors are expanding from a single drug mechanism to become a therapeutic platform targeting various autoimmune diseases. As Vyvgart, the leading product from argenx, has demonstrated commercial viability, the range of indications for FcRn therapies is broadening to include conditions such as rheumatoid and dermatological diseases. In Korea, HanAll Biopharma and Celltrion are developing FcRn-based novel drugs, and attention is focused on HanAll Biopharma's clinical results set to be released later this year.


According to argenx on July 31, Vyvgart's second-quarter sales reached 1.516 billion dollars (approximately 2.1614 trillion won), a 60% increase compared to the same period last year. Vyvgart is a therapy that reduces pathogenic IgG autoantibodies that cause autoimmune diseases. It is used to treat rare conditions such as generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Vyvgart is essentially argenx's only commercialized product, and sales have increased for 18 consecutive quarters since its launch in 2022.


Beyond Rare Diseases, New Horizons Open for Autoimmune Markets... Korean Biopharma Accelerates View original image

Reducing Pathogenic Antibodies... Potential for Expanded Indications

The FcRn is responsible for preventing antibodies in the body from being eliminated too quickly by recycling them back into the bloodstream. The problem is that pathogenic autoantibodies, which cause autoimmune diseases, also use this pathway to persist for longer in the body. FcRn inhibitors block this pathway, allowing pathogenic antibodies to be naturally degraded. Unlike conventional therapies that act on specific inflammatory signaling pathways, FcRn inhibitors target a pathway commonly used by various antibody-mediated diseases, giving the advantage of applying a single drug mechanism to a range of conditions.


Currently, the Vyvgart product lineup has secured three indications: gMG and CIDP in the United States, and primary immune thrombocytopenia (ITP) in Japan. These are representative autoimmune diseases in which pathogenic autoantibodies play a role in disease development. According to argenx's estimates, there are about 58,000 patients with gMG and about 42,000 with CIDP in the United States. UCB and Johnson & Johnson have also launched FcRn inhibitors and entered the market.


argenx's next target is rheumatic diseases. The first focus is autoimmune myositis, a disease in which the immune system attacks muscle tissue, causing inflammation and muscle weakness. The company considers the clinical results for myositis, set to be announced in the third quarter this year, to be its most important clinical achievement of the year. If efficacy is confirmed, the application scope of FcRn inhibitors will expand from neuroimmune diseases to rheumatic diseases. Development for other autoimmune diseases, such as Sjogren's syndrome and Graves' disease, is also expected to accelerate.


HanAll Leads in Clinical Trials... Celltrion Also Joins the Race

In Korea, HanAll Biopharma's FcRn inhibitor candidate, IMVT-140, is the most advanced. Developed by HanAll Biopharma and licensed to Immunovant, this substance is undergoing clinical trials for six indications: difficult-to-treat rheumatoid arthritis (D2T RA), Graves' disease, myasthenia gravis, CIDP, Sjogren's syndrome, and cutaneous lupus erythematosus (CLE). Immunovant estimates there are about 85,000 major D2T RA patients and about 75,000 CLE patients with insufficient response to existing therapies in the United States.


According to interim results released in May for the Phase 2b clinical trial in D2T RA, among 165 evaluable patients who received open-label treatment for 16 weeks, the ACR20, 50, and 70 response rates were 72.7%, 54.5%, and 35.8%, respectively. ACR20, 50, and 70 represent the proportions of patients with 20%, 50%, and 70% or greater improvement in composite indicators including tender/swollen joint count and assessments by patients and physicians. Immunovant plans to announce further results from the D2T RA clinical trial and topline proof-of-concept (PoC) data from the Phase 2b CLE trial in the second half of the year.


Celltrion also acquired the rights to two antibody new drug candidates, including an FcRn inhibitor, from KyMab USA in November last year for up to 1.062 trillion won. Among them, the preclinical-stage FcRn inhibitor CT-P77 was secured with global rights (excluding China and Japan) and is being developed as a long-acting therapy intended for monthly administration.



With latecomers joining the race, competition in the FcRn market is expected to hinge on the preemption of indications and commercialization capabilities. In a recent report, researcher Minjung Kim from DS Investment & Securities analyzed, "There is limited clinical efficacy differentiation among products within the same FcRn mechanism. Currently, the most important factor on the market is the timing of products' launch for each indication. In general, if efficacy differences are minor, the release date significantly impacts the market share of each product."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing